行情

CAPR

CAPR

Capricor
NASDAQ

实时行情|Nasdaq Last Sale

1.180
+0.080
+7.27%
盘后: 1.180 0 0.00% 19:57 04/07 EDT
开盘
1.250
昨收
1.100
最高
1.260
最低
1.140
成交量
297.45万
成交额
--
52周最高
8.85
52周最低
0.8800
市值
1,051.20万
市盈率(TTM)
-0.5554
分时
5日
1月
3月
1年
5年

分析师评级

2位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

目标价格预测

分析师预测CAPR价格均价为6.50,最高价位9.00,最低价为4.000。

EPS

CAPR 新闻

更多
  • Twitter创始人宣布捐献10亿美元抗击新冠病毒
  • 新浪科技 · 1小时前
  • 特朗普:美国将研究暂扣为世卫组织提供的资金
  • 新浪美股 · 1小时前
  • 隔夜要闻:道指回吐逾900点涨幅 美油下挫逾9%
  • 新浪美股 · 1小时前
  • 桥水达利欧:当印刷机不断印钞 仍认为现金就是垃圾
  • 新浪美股 · 1小时前

所属板块

生物技术和医学研究
-2.89%
制药与医学研究
-0.82%

热门股票

代码
价格
涨跌幅

CAPR 简况

Capricor Therapeutics, Inc. is a clinical-stage biotechnology company focused on the discovery, development and commercialization of therapeutics. The Company focuses on discovering, developing and commercializing regenerative medicine and large molecule products for the treatment of disease, with a primary focus on the treatment of cardiovascular diseases, including orphan indications. Its product candidate, CAP-1002, a cardiosphere-derived cell product, is being tested in the ALLSTAR Phase II clinical study on patients having suffered a myocardial infarction (MI), while the DYNAMIC clinical study is testing CAP-1002 in patients in the advanced-stage of heart failure. CAP-1002 is also being tested in the HOPE-Duchenne Phase I/II clinical study for use in connection with Duchenne muscular dystrophy-related cardiomyopathy. Cenderitide, a dual receptor natriuretic peptide agonist, is being tested in a Phase II clinical study. Exosomes are nano-sized, membrane-enclosed vesicles.
展开

微牛提供Capricor Therapeutics Inc(NASDAQ-CAPR)的股票价格,实时市场报价,专业分析师评级,深度图表和免费的CAPR股票新闻,以帮助您做出投资决策。